Iovance Biotherapeutics, Inc.
IOVA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001425205
No open-market purchases or sales by Iovance Biotherapeutics, Inc. insiders were filed in the last 90 days; 293 institutions reported holding it in 13F filings for Q2 2026, worth $1.19B in total; no superinvestor holds it.
Holders of 5% or more of IOVA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Iovance Biotherapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 6.40%21.3M shares | – | Jul 17, 20251 filing | Jul 17, 2025 | SEC |
| State Street Corp | 13G | 5.10%20.2M shares | New | Feb 9, 20261 filing | Feb 9, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
6 Schedule 13D and 13G filings on Iovance Biotherapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 27, 20269:52 AM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −7.50 ppfrom 7.50%Below 5% | Mar 13, 2026 | SEC |
| Feb 9, 20266:43 AM ET | State Street Corp | 13G | 5.10%20.2M shares | New | Dec 31, 2025 | SEC |
| Jul 29, 20251:46 PM ET | Vanguard Group Inc | 13G/A | 7.50%25.1M shares | – | Jun 30, 2025 | SEC |
| Jul 17, 20258:12 PM ET | BlackRock, Inc. | 13G/A | 6.40%21.3M shares | – | Jun 30, 2025 | SEC |
| May 15, 20254:30 PM ET | Perceptive Advisors LLCand 2 others | 13G/A | 3.80%12.8M shares | −3.50 ppfrom 7.30%Below 5% | Mar 31, 2025 | SEC |
| Feb 14, 20254:15 PM ET | Perceptive Advisors LLCand 2 others | 13G/A | 7.30%22.1M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Iovance Biotherapeutics, Inc. shares.
No Form 144 notices for Iovance Biotherapeutics, Inc. are on file.